Twenty-five years ago, Paul Gelsinger’s son Jesse, who suffered from a rare genetic condition, joined a clinical trial for gene-therapy. Tragically, Jesse became the first person to die because of his participation in gene-therapy research. To honor his son’s memory, Paul Gelsinger became a patient advocate, working since 2000 to change the gene-therapy research culture. Join us for a discussion on the last quarter century of human-subjects research trials.